CVS Drops Lilly’s Zepbound as Preferred Drug in Win for Novo

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its members, a blow to rival Eli Lilly & Co.’s Zepbound that was moved off the company’s list of preferred drugs.

The move would save some health plans 10% to 15% on annual anti-obesity medicine costs, a CVS spokesperson said.